Redefining the possible

We are a life science tools company developing a state-of-the-art platform technology uniquely capable of mining a rich seam of new insights from the “dynamic genome”, with significant commercial potential in clinical diagnostics and translational research.

Backed by world-class investors & advisors

Backed by world-class investors & advisors

Over €30M equity & grant money raised to date

Over €30M equity & grant money raised to date

Spin-out from one of France’s top universities

Spin-out from one of France’s top universities

Offices & labs in both Paris and Cambridge, UK

Offices & labs in both Paris and Cambridge, UK

A collaborative & dynamic environment at the cutting edge of science

A collaborative & dynamic environment at the cutting edge of science

We have assembled a talented multidisciplinary team from around the world to bring MAGNATM to market

Leadership

Gordon Hamilton MA MBBS MBA

President (CEO) & Board Member

Steve Allen PhD

Chief Business Officer & Board Member

Jimmy Ouellet PhD

Chief Scientist

Thibault Vieille PhD

Director of Engineering – Optical Systems

Carl Glasse

Director of Engineering – Research

Board

John Berriman

Chairman

Ronald Lindsay

Board Member

Mark Chin

Board Member

Lachlan MacKinnon

Board Member

Thibault Roulon

Board Member

David Bensimon

David Bensimon

Vincent Croquette

Vincent Croquette

Jean-François Allemand

Jean-François Allemand

From academic innovation to commercial reality

Depixus® is built on the foundations of the pioneering biophysics research of David Bensimon, Vincent Croquette, & Jean-François Allemand.

Our partners and investors

Seed & Series A investor

Seed & Series A investor

Series A investor

Series A investor

Grant awards

Grant awards & Series A investor

Series A investor

Series A investor

Laureate in France’s Worldwide Innovation Competition

Laureate in France’s Worldwide Innovation Competition

£0.6m Innovate UK grant

£0.6m Innovate UK grant

£0.36m Eurostars grant

£0.36m Eurostars grant

€2.05m grant from the EU’s H2020 SME Instrument Phase 2 program

€2.05m H2020 SME Instruments Phase 2 grant